Belgian Hematological Society

Recent papers from Belgian Hematological Society

1. Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG StudyBlood · 2016
2. Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple MyelomaBlood · 2014
3. Reference Curve for the First-Year Growth Response to Growth Hormone Treatment in Prepubertal Children with Idiopathic Growth Hormone Deficiency: Validation of the KIGS First-Year Growth Response Curve Using the Belgian Register for the Study of Growth and Puberty ProblemsHormone Research in Paediatrics · 2014
4. Insulin Sensitivity Modulates the Growth Response during the First Year of High-Dose Growth Hormone Treatment in Short Prepubertal Children Born Small for Gestational AgeHormone Research in Paediatrics · 2012
5. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myelomaEuropean Journal Of Haematology · 2011
6. High Body Mass Index (BMI) as a Predictor of Differentiation Syndrome (DS) In Acute Promyelocytic Leukemia (APL).Blood · 2010
7. Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL 2000) From the French Belgian Swiss APL GroupBlood · 2010
8. Do Early Events Excluding Patients with Acute Promyelocytic Leukemia (APL) From Trial Enrollment Modify Treatment Result Evaluation? Real-Life Management of 100 Patients Referred to the University Hospital Saint-Louis Between 2000 and 2010.Blood · 2010
9. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA studyEuropean Journal Of Haematology · 2010
10. Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–PrednisoneBlood · 2008
11. Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple MyelomaBlood · 2008
12. Darbepoetin-Alfa and I.V. Iron Administration after Autologous Hematopoietic Stem Cell Transplantation: A Prospective Randomized Multicenter TrialBlood · 2008
13. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine · 2008
14. Concerns, Expectations and Perception Regarding Stature, Physical Appearance and Psychosocial Functioning before and during High-Dose Growth Hormone Treatment of Short Pre-pubertal Children Born Small for Gestational AgeHormone Research in Paediatrics · 2008
15. Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986-2001European Journal of Endocrinology · 2004
16. High-dose growth hormone treatment of short children born small for gestational age.The Journal of Clinical Endocrinology & Metabolism · 1996
17. Pubertal Growth and Final Height in Hypopituitary Boys: A Minor Role of Bone Age at Onset of Puberty*The Journal of Clinical Endocrinology & Metabolism · 1986